Acurx Pharmaceuticals, INC S-1 registration statements

Acurx Pharmaceuticals, Inc. has filed a Form S-1 registration statement to allow Lincoln Park Capital Fund, LLC to resell up to 1,300,000 shares of common stock.

Acurx Pharmaceuticals, Inc. has filed a Form S-1 with the SEC to register for resale up to 1,650,170 shares of its common stock issuable upon exercise of Series H warrants.

Acurx Pharmaceuticals files an S-1 registration statement for the resale of up to 750,000 common shares by Lincoln Park Capital Fund, LLC, potentially raising up to $7.6 million for the company.

Acurx Pharmaceuticals filed an S-1 registration statement for the resale of up to 585,000 common shares by Lincoln Park Capital Fund, LLC, enabling the company to potentially raise an additional $9.0 million.

A biopharmaceutical company is registering a significant resale of common stock by existing holders, while grappling with Nasdaq non-compliance issues and a 'going concern' audit opinion, signaling substantial financial challenges.

Acurx Pharmaceuticals has filed a registration statement for the resale of up to 10,899,258 shares of its common stock by Lincoln Park Capital Fund, LLC.

Acurx Pharmaceuticals is registering the resale of up to 8,399,700 shares of its common stock by selling stockholders, primarily related to warrant exercises.

Acurx Pharmaceuticals is registering for resale 2.6 million shares of common stock previously issued or issuable upon exercise of warrants to certain investors.

Acurx Pharmaceuticals is offering 12,019,230 shares of common stock to raise approximately $22.9 million for working capital and clinical trials.

Acurx Pharmaceuticals is seeking to raise capital through a common stock offering to support its clinical trials, research and development activities, and other general corporate purposes.